Enlivex Therapeutics -€0.01 -0.93% Friday 06:04
1D 1W 1M 3M 1Y 5Y
2 Dec Expected
This list is based on the watchlists of people on Stock Events who follow 1BT.F. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap 799.17M
Mesoblast Limited focuses on the development of regenerative medicine, which competes directly with Enlivex's cell therapy approach for inflammatory conditions. Fate Therapeutics
FATE
Mkt Cap 417.93M
Fate Therapeutics is involved in the development of programmed cellular immunotherapies for cancer and immune disorders, directly competing with Enlivex's immunotherapy treatments. CRISPR Therapeutics
CRSP
Mkt Cap 4.06B
CRISPR Therapeutics is a gene editing company that competes in the broader field of genetic and cell therapies, potentially targeting similar diseases as Enlivex. Novartis
NVS
Mkt Cap 244.75B
Novartis AG, through its advanced cell therapy platforms, competes in developing treatments for inflammatory and autoimmune diseases, similar to Enlivex's focus areas. Gilead Sciences
GILD
Mkt Cap 98.35B
Gilead Sciences, with its cell therapy and immunology portfolio, competes in the same therapeutic areas as Enlivex, particularly in treatments for inflammatory and autoimmune diseases. Bluebird bio
BLUE
Mkt Cap 108.22M
Bluebird bio focuses on gene therapies for severe genetic diseases and cancer, competing with Enlivex's approach to treating severe medical conditions through advanced therapies. Allogene Therapeutics
ALLO
Mkt Cap 549.96M
Allogene Therapeutics is developing allogeneic CAR T cell therapies, which could compete with Enlivex's cell-based therapies for cancer and immune disorders. Sangamo Therapeutics
SGMO
Mkt Cap 176.57M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the innovative treatment space alongside Enlivex. Adaptimmune Therapeutics
ADAP
Mkt Cap 324.8M
Adaptimmune Therapeutics works on T-cell therapy to treat cancer, directly competing with Enlivex's immunotherapeutic approaches for oncology. Biomarin Pharmaceutical
BMRN
Mkt Cap 17.36B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments for rare genetic diseases, competing with Enlivex's focus on severe and life-threatening conditions.
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Show more...